Lilly Left Nektar Drug 'Damaged Goods,' Jury Told At Trial End

By Bonnie Eslinger · September 18, 2026, 11:38 PM EDT

Eli Lilly & Co. turned Nektar Therapeutics' autoimmune-disease drug Rezpeg into "damaged goods" by breaching the companies' co-development deal and delaying the medication's development in favor of a competing drug the...

To view the full article, register now.
Try a seven day FREE Trial

Already a subscriber? Click here to login

Related Sections

Case Information

Case Title

Nektar Therapeutics v. Eli Lilly & Co

Case Number

3:23-cv-03943

Court

California Northern

Nature of Suit

Contract: Other

Date Filed

August 07, 2023